DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes

Abstract

Background: Oral squamous cell carcinoma (OSCC) is the sixth most common malignancy worldwide. Cancer development and progression require inactivation of tumor suppressor genes and activation of proto-oncogenes. The well recognized mechanism of action demonstrated for chemotherapeutic agents is induction of apoptosis via reactivation of p53. In this context, we evaluate the efficacy of IV and oral routes of our novel PH and temperature sensitive doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) in affecting p53 profile in an OSCC rat model. Methods: In this study, 120 male rats were divided into 8 groups of 15 animals each. The new formulated DOX-MTX NP and free doxorubicin were IV and orally given to rats with 4-nitroquinoline-1-oxide induced OSCC. Results: Results showed that both DOX and DOX-MTX-NP caused significant increase in mRNA levels of P53 compared to the untreated group (p<0.000). With both DOX and DOX-MTX NP, the IV mode was more effective than the oral (gavage) route (p<0.000). Surprisingly, in oral mode, p53 mRNA was not affected in DOX treated groups (p>0.05), Nonetheless, both IV and oral administration of MTX-DOX NP showed superior activity (~3 fold) over free DOX in reactivation of p53 in OSCC (p<0.000). The effectiveness of oral route in group treated with nanodrug accounts for the enhanced bioavailability of nanoparticulated DOX-MTX compared to free DOX. Moreover, in treated groups, tumor stage was markedly related to the amount of p53 mRNA (p<0.05). Conclusion: Both oral and IV application of our novel nanodrug possesses superior activity over free DOX-in up-regulation of p53 in a OSCC model and this increase in p53 level associated with less aggressive tumors in our study. Although, impressive results obtained with IV form of nanodrug (-21 fold increase in p53 mRNA level) but both forms of nanodrug are effective in OSCC, with less toxicity normal cells.

Induction of oxidative stress and cell apoptosis by selenium: the cure against oral carcinoma

“…Despite efforts to improve overall outcomes, survival rates have not changed during the last 20 years [ 5 ]. Tongue cancer is the most common oral cavity neoplasm with an unfavorable prognosis and high metastatic potential [ 6 ]. Patients with premalignant lesions and early stage cancers have a high rate of survival, but the vast majority of Stages III and IV cases are fatal [ 7 ].…”

Anti Proliferative Properties of Melissa officinalis in Different Human Cancer Cells

“…In our study, DPPH IC50 was obtained at 2.9µg/ml which indicates to the high antioxidant activity of Persian MOE compared to MO extract from Spain. In course of our interest on toxicological properties of different medicinal plants towards aggressive tumors (Abbasi et al, 2014a), in following study, we investigated the selective cytotoxicity of MO extract on a series of human cancers including ovarian cancer cells (SKOV3), breast adenocarcinoma cells (MCF-7), prostate adenocarcinoma cells (PC-3) and lung non small cancer cells (A549) by MTT assay. In course our interest on treatment of aggressive tumors; we specially selected these cancer cells because each displays a high propensity for metastasis in vivo.…”

Combination of nanotechnology with vascular targeting agents for effective cancer therapy

“…These data imply that oral immunization with BFGF/PCEC NPs can be used as an effective anti‐angiogenesis vaccine in cancer immunotherapy (Long et al, ). Stimuli‐responsive cationic mesoporous silica NPs fabricated by the us was employed for co‐delivery of Doxorubicin/Methotrexate (DOX‐MTX) to cancer cells in vitro and in vivo (Abbasi, Khiavi et al, ). The dual temperature and pH responsive NPs were selectively accumulated at the tumor site and enabled simultaneous delivery of chemotherapeutics.…”

“…Multi‐targeting is an additional benefit of the nanostructures. The simultaneous targeting of several angiogenic markers for effective cancer therapy is feasible through the development of multi‐targeting nanosystems (Abbasi, Khiavi et al, ). Co‐conjugation of cRGD and anginex to liposomes create a dual‐targeting therapeutic and diagnostic tool which produces synergistic anti‐angiogenic potential through targeting two prominent angiogenesis‐related molecules, α v β 3 , and Galectin‐1, respectively (Kluza et al, ).…”